X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Carmell Therapeutics is in early preclinical testing of BHA product as an orthobiolgoic to determine the capability of BHA to act as an enhancer to existing bone graft substitutes as well as a stand-alone new alternative to bone graft substitute products.
Lead Product(s): Allogeneic Plasma-based Biomaterial,Calcium Phosphate
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: BHA
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alpha Healthcare Acquisition Corp.
Deal Size: $154.0 million Upfront Cash: Undisclosed
Deal Type: Merger January 04, 2023
Details:
The Fast Track status offers the company benefits in improving and accelerating the company's trial on Bone Healing Accelerant in open tibia fractures to the target of a Biologic License Application.
Lead Product(s): Calcium Phosphate,Blood-derived component
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Details:
Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.
Lead Product(s): Calcium Phosphate
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
